Exciting advancements in acute myeloid leukemia (AML) research were discussed during the American Society of Hematology (ASH) 2017 Annual Meeting and Exposition, held in Atlanta, GA. There has recently been a revolution in targeted treatments for AML, according to Francesco Lo-Coco, MD, of University Tor Vergata, Rome, Italy. In this interview, Dr Lo-Coco discusses the latest developments in targeted treatments, which include anti-CD33 monoclonal antibodies, the Bcl-2 inhibitor venetoclax in combination with low-dose cytarabine (investigated in a Phase Ib/II open-label study; NCT02287233) and IDH2 inhibitors. Dr Lo-Coco also highlights the importance of minimal residual disease (MRD) in future trials.
Targeted treatments for AML: the revolution
